339222
Clinical trials of opioid pharmacotherapies in criminal justice system populations
of MAT in CJS populations, which alongside international health services data, establish the rationale for more broadly implementing and disseminating these interventions. A review of the evidence will include: outcomes for HIV+ prisoners at re-entry linking buprenorphine uptake and improved HIV markers; buprenorphine vs. methadone NYC jail RCT; XR-NTX relapse prevention for persons leaving jails and among community-dwelling parolees and probationers; multiple RCT focused on the implementation of pre-release methadone maintenance for treatment of opioid dependence. Summary discussion will consider the practical barriers to MAT implementation and implications for overdose prevention, community addiction treatment, and chronic disease management.
Learning Areas:
Basic medical science applied in public healthClinical medicine applied in public health
Ethics, professional and legal requirements
Implementation of health education strategies, interventions and programs
Protection of the public in relation to communicable diseases including prevention or control
Public health or related public policy
Learning Objectives:
Describe the rationale for MAT trials among CJS involved opioid dependent populations, consider the strength of evidence supporting the use of buprenorphine, methadone, and XRnaltrexone
as pre-release interventions, and discuss the context of typical systems and policy barriers to wider CJS-MAT dissemination
and implementation.
Qualified on the content I am responsible for because: I am the PI of multiple NIH trials of opioid and alcohol pharmacotherapies among criminal justice and primary care
populations. Our research agenda concerns expanding access and effective treatment options for these common addictive
disorders.
Any relevant financial relationships? Yes
| Name of Organization | Clinical/Research Area | Type of relationship |
|---|---|---|
| Alkermes, Inc. | In-Kind Study Drug | Employment (includes retainer) |
| Reckitt-Benkiser | In-Kind Study Drug | Employment (includes retainer) |
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.